title: [Salvage combination chemotherapy with cytarabine, carboplatin and steroids for relapsed or refractory non-Hodgkin's lymphoma].
abstract: We have treated 29 patients (19 men and 10 women) with relapsed or refractory non-Hodgkin's lymphoma with a combination of cytarabine (Ara-C), carboplatin (CBDCA) and prednisolone (PSL). The regimen, on days 1 to 3, included Ara-C, 400 mg/m2 i.v.; CBDCA; 250 mg/m2 i.v.; and PSL, 40 mg/m2. Since complete response was achieved in 10 patients (34.5%) and partial response in 9 (31.0%), the total response rate was 65.5%. The 50% survival duration of all patients after the initiation of this therapy was 8 months. The overall 5-year survival rate was 66.7% for those who achieved CR or PR with the Ara-C/CBDCA regimen and received high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Myelosuppression was the major toxicity. Total WBC counts under 1,000/microliter were seen in 67.7% of the courses, and thrombocytopenia under 50,000/microliter was seen in 96.8%. Ara-C/CBDCA has proven to be an effective salvage regimen for patients with relapsed or refractory lymphoma. High-dose chemotherapy and autologous hematopoietic stem cell transplantation should be considered for salvageable patients.
authors.affiliation: Dept. of Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University.
authors.forename: Ryousuke
authors.initials: R
authors.lastname: Yamamura
authors.forename: Takahisa
authors.initials: T
authors.lastname: Yamane
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Aoyama
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Nakamae
authors.forename: Tarou
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Kensuke
authors.initials: K
authors.lastname: Ohta
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Nakao
authors.forename: Tadanobu
authors.initials: T
authors.lastname: Ohta
authors.forename: Atsuko
authors.initials: A
authors.lastname: Mugitani
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hino
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D012008:Recurrence; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D011239:Prednisolone; D016190:Carboplatin